Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Indivior ( (INDV) ) just unveiled an update.
Indivior PLC has launched the Indivior Action Agenda, a multi-year operational roadmap to enhance its business potential and impact on opioid use disorder treatment. As part of Phase 1, the company is implementing initiatives to simplify its organization, including headcount reductions and real estate consolidations, expecting to incur restructuring charges of $39 to $50 million in 2025. Additionally, Indivior is exploring strategic alternatives for OPVEE® and its non-U.S. business, which could lead to further cost savings.
The most recent analyst rating on (INDV) stock is a Hold with a $1288.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
Spark’s Take on INDV Stock
According to Spark, TipRanks’ AI Analyst, INDV is a Neutral.
Indivior’s overall stock score is driven by strong earnings call performance and positive corporate events, offset by financial instability and lack of technical analysis data. The company’s strategic initiatives and improved guidance provide a positive outlook, but financial and valuation concerns remain.
To see Spark’s full report on INDV stock, click here.
More about Indivior
Indivior PLC operates in the pharmaceutical industry, focusing primarily on developing treatments for opioid use disorder (OUD). The company’s key product is SUBLOCADE, a long-acting injectable aimed at treating OUD, with a significant market focus in the United States.
Average Trading Volume: 2,776,323
Technical Sentiment Signal: Buy
Current Market Cap: $3B
See more data about INDV stock on TipRanks’ Stock Analysis page.